Evaluation of Immunomodulatory Effect of Immunace on Adjuvanticity of 1,2-Dioleoyl-3- trimethylammoniumpropane-based Liposomes
Purpose: To investigate the antibody effect of immunace on the adjuvanticity of 1,2-dioleoyl-3- trimethylammoniumpropane (DOTAP)- based liposomes.
Method: The vesicles of the liposome-based ND vaccine were prepared by lipid film hydration method and physically characterized for shape, particle size and zeta potential. Forty experimental birds were divided into an unvaccinated group, a liposomal Newcastle disease (ND) vaccine group, combined liposomal ND vaccine and immunace group, and a live La Sota® vaccine group. The liposomal ND vaccine, liposomal ND vaccine and immunace and a live La Sota® vaccine groups were vaccinated orally at 3 and 6 weeks of age. Haemagglutination inhibition test was carried out after primary and booster doses.
Results: The log2 mean antibody titre induced by the liposomal ND vaccine after secondary immunization of the birds was 9.60 ± 0.95 while that of the combined liposomal ND vaccine and immunace group was 7.00 ±1.71, and that of the live La Sota vaccine® was 6.00 ±0.63. There was no detectable antibody in the unvaccinated group throughout the experiment. At p < 0.05, the liposomal ND vaccine group, after secondary immunization, produced antibodies which were significantly higher than those of the combined immunace-liposomal ND vaccine group.
Conclusion: There was a boost in the immune response of the birds immunized with liposomal ND vaccine and immunace after primary immunization only.
Keywords: Antibody, Newcastle disease vaccine, La Sota, DOTAP, Immunace, Immunity, Adjuvant
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.